Here is a great dementia resource for caregivers and healthcare professinals,
Here is information on being the best caregiver you can be
Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two
Follow Alzheimers1 on twitter
news-medical.net
The brain damage that characterizes Alzheimer's disease may originate in a form similar to that of infectious prion diseases such as bovine spongiform encephalopathy (mad cow) and Creutzfeldt-Jakob, according to newly published research by The University of Texas Health Science Center at Houston (UTHealth).
"Our findings open the possibility that some of the sporadic Alzheimer's cases may arise from an infectious process, which occurs with other neurological diseases such as mad cow and its human form, Creutzfeldt-Jakob disease," said Claudio Soto, Ph.D., professor of neurology at The University of Texas Medical School at Houston, part of UTHealth. "The underlying mechanism of Alzheimer's disease is very similar to the prion diseases. It involves a normal protein that becomes misshapen and is able to spread by transforming good proteins to bad ones. The bad proteins accumulate in the brain, forming plaque deposits that are believed to kill neuron cells in Alzheimer's."
The results showing a potentially infectious spreading of Alzheimer's disease in animal models were published in the Oct. 4, 2011 online issue of Molecular Psychiatry, part of the Nature Publishing Group. The research was funded by The George P. and Cynthia W. Mitchell Center for Research in Alzheimer's Disease and Related Brain Disorders at UTHealth.
Alzheimer's disease is a form of progressive dementia that affects memory, thinking and behavior. Of the estimated 5.5 million cases of Alzheimer's in the United States, 90 percent are sporadic. The plaques caused by misshapen aggregates of beta amyloid protein, along with twisted fibers of the protein tau, are the two major hallmarks associated with the disease. Alzheimer's is the sixth leading cause of death in the United States, according to the Alzheimer's Association.
Researchers injected the brain tissue of a confirmed Alzheimer's patient into mice and compared the results to those from injected tissue of a control without the disease. None of the mice injected with the control showed signs of Alzheimer's, whereas all of those injected with Alzheimer's brain extracts developed plaques and other brain alterations typical of the disease.
"We took a normal mouse model that spontaneously does not develop any brain damage and injected a small amount of Alzheimer's human brain tissue into the animal's brain," said Soto, who is director of the Mitchell Center. "The mouse developed Alzheimer's over time and it spread to other portions of the brain. We are currently working on whether disease transmission can happen in real life under more natural routes of exposure."
Source: University of Texas Health Science Center at Houston
Susan Berg, dementia expert, shares practical help for caregivers of those with dementia including easy to do activities
Monday, October 31, 2011
Saturday, October 29, 2011
Blood Test Predicts Course of Alzheimer's
Here is a great dementia resource for caregivers and healthcare professinals,
Here is information on being the best caregiver you can be
Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two
Follow Alzheimers1 on twitter.
By Crystal Phend, Senior Staff Writer, MedPage Today
Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco and
Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planne
Plasma levels of sphingolipid compounds can predict progression of Alzheimer's disease, a small, early, observational study showed.
Higher ratios of sphingomyelins to ceramide and of dihydrosphingomyelin to dihydroceramides predicted significantly slower clinical progression, Michelle M. Mielke, PhD, of Johns Hopkins University, and colleagues found. Mielke is now at Mayo Clinic in Rochester, Minn.
If validated, sphingolipids could be "a sensitive, and easily accessible, biomarker" for Alzheimer's progression, they reported online in the Journal of Alzheimer's Disease.
That would be a big advantage for families and caregivers and also may help in development of better treatments for Alzheimer's, the group suggested.
Sphingolipids play a critical role in cellular signaling as major components of cell membranes, particularly in the central nervous system, where the proper balance of different species of these fats is essential for normal function of neurons.
The researchers correlated sphingolipid levels measured in 120 patients with probable Alzheimer's disease, predominantly of mild to moderate severity, at a single center. They were followed for progression over 2.3 years on average.
Higher levels of the various sphingolipids didn't predict more severe dementia at baseline, but they did predict rate of decline.
Higher dihydroceramides predicted significantly greater decline on the Mini-Mental State Exam (MMSE, P=0.050 as a continuous variable), while ceramides showed a similar but nonsignificant trend.
On the other hand, plasma sphingomyelins at higher levels predicted less progression on the MMSE (1.15 points difference for highest versus lowest tertile, P=0.006).
The same was true for dihydrosphingomyelin, with the top tertile progressing by 0.84 fewer points than those in the bottom tertile (P=0.046).
But the strongest predictors were ratios of metabolically-linked pairs of these lipids.
Ceramides are both a precursor for sphingomyelins and can be formed by their catabolism, and the same is true for the dihydro form of both.
The ratio of sphingomyelins to ceramides was associated with 1.19-points less decline on the MMSE (P=0.004) and 2.42-points less worsening on the Alzheimer's Disease Assessment Scale-Cognitive Subscale for the top versus bottom tertile (P=0.016).
The ratio of dihydrosphingomyelins to dihydroceramides correlated with a decline of 1.35 fewer points on the MMSE and an increase of 3.18 fewer points on the cognitive scale (both P=0.001).
"Together, these results suggest a shift in the metabolic pathways from ceramide to sphingomyelins over the course of Alzheimer's disease," such that the ratios may be useful predictors of clinical progression in later stages of the disease, Mielke's group suggested in the paper.
Total cholesterol and triglycerides didn't predict progression of Alzheimer's disease.
The researchers also looked at correlation of all the factors with functional decline measured on the Clinical Dementia Rating-Sum of Boxes but found no significant predictors.
They cautioned that the lipid levels measured at baseline weren't taken while fasting, which may have affected levels of some plasma sphingolipids.
But controlling for body mass index, diabetes and cardiovascular disease status, as well as other factors in the individuals in whom they were known didn't appear to impact the results.
The study was funded by a grant from George P. Mitchell and the late Cynthia W. Mitchell and by the National Institute of Aging.
The researchers reported having no conflicts of interest to disclose.
Primary source: Journal of Alzheimer's Disease
Source reference:
Mielke MM, et al "Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease" J Alzheimers Dis 2011; DOI: 10.3233/JAD-2011-110405.
Here is information on being the best caregiver you can be
Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two
Follow Alzheimers1 on twitter.
By Crystal Phend, Senior Staff Writer, MedPage Today
Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco and
Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planne
Plasma levels of sphingolipid compounds can predict progression of Alzheimer's disease, a small, early, observational study showed.
Higher ratios of sphingomyelins to ceramide and of dihydrosphingomyelin to dihydroceramides predicted significantly slower clinical progression, Michelle M. Mielke, PhD, of Johns Hopkins University, and colleagues found. Mielke is now at Mayo Clinic in Rochester, Minn.
If validated, sphingolipids could be "a sensitive, and easily accessible, biomarker" for Alzheimer's progression, they reported online in the Journal of Alzheimer's Disease.
That would be a big advantage for families and caregivers and also may help in development of better treatments for Alzheimer's, the group suggested.
Sphingolipids play a critical role in cellular signaling as major components of cell membranes, particularly in the central nervous system, where the proper balance of different species of these fats is essential for normal function of neurons.
The researchers correlated sphingolipid levels measured in 120 patients with probable Alzheimer's disease, predominantly of mild to moderate severity, at a single center. They were followed for progression over 2.3 years on average.
Higher levels of the various sphingolipids didn't predict more severe dementia at baseline, but they did predict rate of decline.
Higher dihydroceramides predicted significantly greater decline on the Mini-Mental State Exam (MMSE, P=0.050 as a continuous variable), while ceramides showed a similar but nonsignificant trend.
On the other hand, plasma sphingomyelins at higher levels predicted less progression on the MMSE (1.15 points difference for highest versus lowest tertile, P=0.006).
The same was true for dihydrosphingomyelin, with the top tertile progressing by 0.84 fewer points than those in the bottom tertile (P=0.046).
But the strongest predictors were ratios of metabolically-linked pairs of these lipids.
Ceramides are both a precursor for sphingomyelins and can be formed by their catabolism, and the same is true for the dihydro form of both.
The ratio of sphingomyelins to ceramides was associated with 1.19-points less decline on the MMSE (P=0.004) and 2.42-points less worsening on the Alzheimer's Disease Assessment Scale-Cognitive Subscale for the top versus bottom tertile (P=0.016).
The ratio of dihydrosphingomyelins to dihydroceramides correlated with a decline of 1.35 fewer points on the MMSE and an increase of 3.18 fewer points on the cognitive scale (both P=0.001).
"Together, these results suggest a shift in the metabolic pathways from ceramide to sphingomyelins over the course of Alzheimer's disease," such that the ratios may be useful predictors of clinical progression in later stages of the disease, Mielke's group suggested in the paper.
Total cholesterol and triglycerides didn't predict progression of Alzheimer's disease.
The researchers also looked at correlation of all the factors with functional decline measured on the Clinical Dementia Rating-Sum of Boxes but found no significant predictors.
They cautioned that the lipid levels measured at baseline weren't taken while fasting, which may have affected levels of some plasma sphingolipids.
But controlling for body mass index, diabetes and cardiovascular disease status, as well as other factors in the individuals in whom they were known didn't appear to impact the results.
The study was funded by a grant from George P. Mitchell and the late Cynthia W. Mitchell and by the National Institute of Aging.
The researchers reported having no conflicts of interest to disclose.
Primary source: Journal of Alzheimer's Disease
Source reference:
Mielke MM, et al "Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease" J Alzheimers Dis 2011; DOI: 10.3233/JAD-2011-110405.
Thursday, October 27, 2011
Study: Apparent cause of accelerated formation of amyloid beta in Alzheimer's disease
Here is a great dementia resource for caregivers and healthcare professinals,
Here is information on being the best caregiver you can be
Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two
Follow Alzheimers1 on twitter
Cell Press
In their study, first author Dr. Markus P. Kummer and colleagues discovered that amyloid beta(AΒ) is a novel nitric oxide(NO) target. They observed nitrated AΒ in Alzheimer's disease(AD) and AD mouse models and found that this modification accelerated the deposition of human AΒ. Importantly, reduction of nitric oxide synthase(NOS2) reduced AΒ deposition and memory deficits in a mouse model of AD. Further, nitrated AΒ induced the formation of amyloid plaques when injected into the brains of mice with genetic mutations associated with AD.
"Taken together, our results identify a novel modification of AΒ, tyrosine nitration, and propose a causative link between the AΒ cascade, activation of NOS2, and the subsequent increase in its reaction product nitric oxide during AD," concludes Dr. Heneka. "We think that nitrated AΒ may serve as marker of early AΒ plaque formation. More importantly, it may be a promising target for an AD therapy, and that application of specific inhibitors of NOS2 may therefore open a new therapeutic avenue in AD."
Here is information on being the best caregiver you can be
Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two
Follow Alzheimers1 on twitter
Cell Press
In their study, first author Dr. Markus P. Kummer and colleagues discovered that amyloid beta(AΒ) is a novel nitric oxide(NO) target. They observed nitrated AΒ in Alzheimer's disease(AD) and AD mouse models and found that this modification accelerated the deposition of human AΒ. Importantly, reduction of nitric oxide synthase(NOS2) reduced AΒ deposition and memory deficits in a mouse model of AD. Further, nitrated AΒ induced the formation of amyloid plaques when injected into the brains of mice with genetic mutations associated with AD.
"Taken together, our results identify a novel modification of AΒ, tyrosine nitration, and propose a causative link between the AΒ cascade, activation of NOS2, and the subsequent increase in its reaction product nitric oxide during AD," concludes Dr. Heneka. "We think that nitrated AΒ may serve as marker of early AΒ plaque formation. More importantly, it may be a promising target for an AD therapy, and that application of specific inhibitors of NOS2 may therefore open a new therapeutic avenue in AD."
Tuesday, October 25, 2011
Could taking vitamin C help those with dementia
Here is a great dementia resource for caregivers and healthcare professinals,
Here is information on being the best caregiver you can be
Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two
Times of India
Taking vitamin C might help patients with Alzheimer's disease, a study has suggested.
According to Lund University researchers, treatment with vitamin C can dissolve the toxic protein aggregates that build up in the brain in Alzheimer's disease.
The brains of people with Alzheimer's disease contain lumps of so-called amyloid plaques, which consist of misfolded protein aggregates. They cause nerve cell death in the brain and the first nerves to be attacked are the ones in the brain's memory centre.
"When we treated brain tissue from mice suffering from Alzheimer's disease with vitamin C, we could see that the toxic protein aggregates were dissolved. Our results show a previously unknown model for how vitamin C affects the amyloid plaques", said Katrin Mani, reader in Molecular Medicine at Lund University.
"Another interesting finding is that the useful vitamin C does not need to come from fresh fruit. In our experiments, we show that the vitamin C can also be absorbed in larger quantities in the form of dehydroascorbic acid from juice that has been kept overnight in a refrigerator, for example," added Mani.
There is at present no treatment that cures Alzheimer's disease, but the research is aimed at treatments and methods to delay and alleviate the progression of the disease by addressing the symptoms.
"The notion that vitamin C can have a positive effect on Alzheimer's disease is controversial, but our results open up new opportunities for research into Alzheimer's and the possibilities offered by vitamin C", said Mani.
The findings have been published in the Journal of Biological Chemistry .
Here is information on being the best caregiver you can be
Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two
Times of India
Taking vitamin C might help patients with Alzheimer's disease, a study has suggested.
According to Lund University researchers, treatment with vitamin C can dissolve the toxic protein aggregates that build up in the brain in Alzheimer's disease.
The brains of people with Alzheimer's disease contain lumps of so-called amyloid plaques, which consist of misfolded protein aggregates. They cause nerve cell death in the brain and the first nerves to be attacked are the ones in the brain's memory centre.
"When we treated brain tissue from mice suffering from Alzheimer's disease with vitamin C, we could see that the toxic protein aggregates were dissolved. Our results show a previously unknown model for how vitamin C affects the amyloid plaques", said Katrin Mani, reader in Molecular Medicine at Lund University.
"Another interesting finding is that the useful vitamin C does not need to come from fresh fruit. In our experiments, we show that the vitamin C can also be absorbed in larger quantities in the form of dehydroascorbic acid from juice that has been kept overnight in a refrigerator, for example," added Mani.
There is at present no treatment that cures Alzheimer's disease, but the research is aimed at treatments and methods to delay and alleviate the progression of the disease by addressing the symptoms.
"The notion that vitamin C can have a positive effect on Alzheimer's disease is controversial, but our results open up new opportunities for research into Alzheimer's and the possibilities offered by vitamin C", said Mani.
The findings have been published in the Journal of Biological Chemistry .
Labels:
.dementia,
alzheimer's disease,
vitamin C
Sunday, October 23, 2011
Cognitive, Not Bio, Markers Predictive of Cognitive Decline
Here is a great dementia resource for caregivers and healthcare professinals,
Here is information on being the best caregiver you can be
Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two
Doctors Lounge
Cognitive markers are more effective predictors of conversion from mild cognitive impairment to Alzheimer's disease than biomarkers, according to a study published in the September issue of the Archives of General Psychiatry.
(HealthDay News) -- Cognitive markers are more effective predictors of conversion from mild cognitive impairment to Alzheimer's disease than biomarkers, according to a study published in the September issue of the Archives of General Psychiatry.
Jesus J. Gomar, Ph.D., from the Benito Menni Complex Assistencial en Salut Mental in Barcelona, Spain, and colleagues investigated the discriminative utility of different classes of biomarkers and cognitive markers by assessing their ability to predict conversion from mild cognitive impairment to Alzheimer's disease. The Alzheimer's Disease Neuroimaging Initiative (ADNI) database was analyzed to study 116 patients with mild cognitive impairment who converted to Alzheimer's disease, and 204 patients who did not convert within a two-year study period. The predictive utility of 25 variables from all classes of markers, biomarkers, and risk factors were determined by logistic regression models and effect size analyses.
The investigators found that, in logistic regression models, which included variables from all classes of markers, two measures of delayed verbal memory and middle temporal lobe cortical thickness predicted conversion within a two-year period. Effect size analyses revealed that biomarkers had modest change scores for two years, but change in an everyday functional activities measure was substantially larger. Approximately 50 percent of the predictive variance in conversion from mild cognitive impairment to Alzheimer's disease was attributed to decline in scores on the Functional Assessment Questionnaire and Trail Making Test, part B.
"We demonstrated that cognitive markers were consistently significant and generally stronger predictors than biomarkers," the authors write.
Two authors disclosed financial ties with the pharmaceutical industry. One of the study authors receives royalties for use of a cognitive test battery in clinical trials. The ADNI database used in the study was funded by the pharmaceutical industry.
Here is information on being the best caregiver you can be
Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two
Doctors Lounge
Cognitive markers are more effective predictors of conversion from mild cognitive impairment to Alzheimer's disease than biomarkers, according to a study published in the September issue of the Archives of General Psychiatry.
(HealthDay News) -- Cognitive markers are more effective predictors of conversion from mild cognitive impairment to Alzheimer's disease than biomarkers, according to a study published in the September issue of the Archives of General Psychiatry.
Jesus J. Gomar, Ph.D., from the Benito Menni Complex Assistencial en Salut Mental in Barcelona, Spain, and colleagues investigated the discriminative utility of different classes of biomarkers and cognitive markers by assessing their ability to predict conversion from mild cognitive impairment to Alzheimer's disease. The Alzheimer's Disease Neuroimaging Initiative (ADNI) database was analyzed to study 116 patients with mild cognitive impairment who converted to Alzheimer's disease, and 204 patients who did not convert within a two-year study period. The predictive utility of 25 variables from all classes of markers, biomarkers, and risk factors were determined by logistic regression models and effect size analyses.
The investigators found that, in logistic regression models, which included variables from all classes of markers, two measures of delayed verbal memory and middle temporal lobe cortical thickness predicted conversion within a two-year period. Effect size analyses revealed that biomarkers had modest change scores for two years, but change in an everyday functional activities measure was substantially larger. Approximately 50 percent of the predictive variance in conversion from mild cognitive impairment to Alzheimer's disease was attributed to decline in scores on the Functional Assessment Questionnaire and Trail Making Test, part B.
"We demonstrated that cognitive markers were consistently significant and generally stronger predictors than biomarkers," the authors write.
Two authors disclosed financial ties with the pharmaceutical industry. One of the study authors receives royalties for use of a cognitive test battery in clinical trials. The ADNI database used in the study was funded by the pharmaceutical industry.
Friday, October 21, 2011
Osteoarthritis accelerates and exacerbates Alzheimer's disease pathology in mice
Here is a great dementia resource for caregivers and healthcare professinals,
Here is information on being the best caregiver you can be
Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two
Journal of Neuroinflammation
tephanos Kyrkanides, Ross H Tallents, Jen-nie H Miller, Mallory E Olschowka, Renee Johnson, Meixiang Yang, John A Olschowka, Sabine M Brouxhon and M. KERRY O'Banion
Abstract (provisional)
Background
The purpose of this study was to investigate whether localized peripheral inflammation, such as osteoarthritis, contributes to neuroinflammation and neurodegenerative disease in vivo.
Method
S We employed the inducible Col1-IL1betaXAT mouse model of osteoarthritis, in which induction of osteoarthritis in the knees and temporomandibular joints resulted in astrocyte and microglial activation in the brain, accompanied by upregulation of inflammation-related gene expression. The biological significance of the link between peripheral and brain inflammation was explored in the APP/PS1 mouse model of Alzheimer's disease (AD) whereby osteoarthritis resulted in neuroinflammation as well as exacerbation and acceleration of AD pathology.
Results
Induction of osteoarthritis exacerbated and accelerated the development of neuroinflammation, as assessed by glial cell activation and quantification of inflammation-related mRNAs, as well as Abeta pathology, assessed by the number and size of amyloid plaques, in the APP/PS1; Col1-IL1betaXAT compound transgenic mouse.
Conclusion
This work supports a model by which peripheral inflammation triggers the development of neuroinflammation and subsequently the induction of AD pathology. Better understanding of the link between peripheral localized inflammation, whether in the form of osteoarthritis, atherosclerosis or other conditions, and brain inflammation, may prove critical to our understanding of the pathophysiology of disorders such as Alzheimer's, Parkinson's and other neurodegenerative diseases.
The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.
Here is information on being the best caregiver you can be
Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two
Journal of Neuroinflammation
tephanos Kyrkanides, Ross H Tallents, Jen-nie H Miller, Mallory E Olschowka, Renee Johnson, Meixiang Yang, John A Olschowka, Sabine M Brouxhon and M. KERRY O'Banion
Abstract (provisional)
Background
The purpose of this study was to investigate whether localized peripheral inflammation, such as osteoarthritis, contributes to neuroinflammation and neurodegenerative disease in vivo.
Method
S We employed the inducible Col1-IL1betaXAT mouse model of osteoarthritis, in which induction of osteoarthritis in the knees and temporomandibular joints resulted in astrocyte and microglial activation in the brain, accompanied by upregulation of inflammation-related gene expression. The biological significance of the link between peripheral and brain inflammation was explored in the APP/PS1 mouse model of Alzheimer's disease (AD) whereby osteoarthritis resulted in neuroinflammation as well as exacerbation and acceleration of AD pathology.
Results
Induction of osteoarthritis exacerbated and accelerated the development of neuroinflammation, as assessed by glial cell activation and quantification of inflammation-related mRNAs, as well as Abeta pathology, assessed by the number and size of amyloid plaques, in the APP/PS1; Col1-IL1betaXAT compound transgenic mouse.
Conclusion
This work supports a model by which peripheral inflammation triggers the development of neuroinflammation and subsequently the induction of AD pathology. Better understanding of the link between peripheral localized inflammation, whether in the form of osteoarthritis, atherosclerosis or other conditions, and brain inflammation, may prove critical to our understanding of the pathophysiology of disorders such as Alzheimer's, Parkinson's and other neurodegenerative diseases.
The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.
Wednesday, October 19, 2011
Antiviral drugs could slow Alzheimer's disease
Here is a great dementia resource for caregivers and healthcare professinals,
Here is information on being the best caregiver you can be
Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two
Follow Alzheimers1 on twitter
University of Manchester
Antiviral drugs used to target the herpes virus could be effective at slowing the progression of Alzheimer’s disease (AD), a new study shows.
The University of Manchester scientists have previously shown that the herpes simplex virus type 1 (HSV1) is a risk factor for Alzheimer’s when it is present in the brains of people who have a specific genetic risk to the disease.
AD is an incurable neurodegenerative condition affecting about 18 million people worldwide. The causes of the disease or of the abnormal protein structures seen in AD brains – amyloid plaques and neurofibrillary tangles – are completely unknown.
The Manchester team has established that the herpes virus causes accumulation of two key AD proteins – β-amyloid (Aβ) and abnormally phosphorylated tau (P-tau) – known to be the main components of plaques and tangles respectively. Both proteins are thought by many scientists to be involved in the development of the disease.
“We have found that the viral DNA in AD brains is very specifically located within amyloid plaques,” said Professor Ruth Itzhaki, who led the team in the University’s Faculty of Life Sciences. “This, together with the production of amyloid that the virus induces, suggests that HSV1 is a cause of toxic amyloid products and of plaques.
“Our results suggest that HSV1, together with the host genetic factor, is a major risk for AD, and that antiviral agents might be used for treating patients to slow disease progression.”
Currently available antiviral agents act by targeting replication of HSV1 DNA, and so the researchers considered that they might be successful in treating AD only if the accumulation of β-amyloid and P-tau accumulation caused by the virus occurs at or after the stage at which viral DNA replication occurs.
“If these proteins are produced independently of HSV1 replication, antivirals might not be effective,” said Professor Itzhaki. “We investigated this and found that treatment of HSV1-infected cells with acyclovir, the most commonly used antiviral agent, and also with two other antivirals, did indeed decrease the accumulation of β-amyloid and P-tau, as well as decreasing HSV1 replication as we would expect.
“This is the first study investigating antiviral effects on AD-like changes and we conclude that since antiviral agents reduce greatly β-amyloid and P-tau levels in HSV1-infected cells, they would be suitable for treating Alzheimer’s disease. The great advantage over current AD therapies is that acyclovir would target only the virus, not the host cell or normal uninfected cells. Further, these agents are very safe and are relatively inexpensive.
“Also, by targeting a cause of Alzheimer’s disease, other viral damage, besides β-amyloid and P-tau, which might be involved in the disease’s pathogenesis, would also be inhibited.
“The next stage of our research – subject to funding – will focus on finding the most suitable antiviral agent – or combination of two agents that operate via different mechanisms – for use as treatment. We then need to investigate the way in which the virus and the genetic risk factor interact to cause the disease, as that might lead to further novel treatments.
“Eventually, we hope to begin clinical trials in humans but this is still some way off yet and again will require new funding.”
The study, carried out with Dr Matthew Wozniak and other colleagues in the Faculty of Life Sciences, is published in the Public Library of Science (PLoS) One journal
Here is information on being the best caregiver you can be
Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two
Follow Alzheimers1 on twitter
University of Manchester
Antiviral drugs used to target the herpes virus could be effective at slowing the progression of Alzheimer’s disease (AD), a new study shows.
The University of Manchester scientists have previously shown that the herpes simplex virus type 1 (HSV1) is a risk factor for Alzheimer’s when it is present in the brains of people who have a specific genetic risk to the disease.
AD is an incurable neurodegenerative condition affecting about 18 million people worldwide. The causes of the disease or of the abnormal protein structures seen in AD brains – amyloid plaques and neurofibrillary tangles – are completely unknown.
The Manchester team has established that the herpes virus causes accumulation of two key AD proteins – β-amyloid (Aβ) and abnormally phosphorylated tau (P-tau) – known to be the main components of plaques and tangles respectively. Both proteins are thought by many scientists to be involved in the development of the disease.
“We have found that the viral DNA in AD brains is very specifically located within amyloid plaques,” said Professor Ruth Itzhaki, who led the team in the University’s Faculty of Life Sciences. “This, together with the production of amyloid that the virus induces, suggests that HSV1 is a cause of toxic amyloid products and of plaques.
“Our results suggest that HSV1, together with the host genetic factor, is a major risk for AD, and that antiviral agents might be used for treating patients to slow disease progression.”
Currently available antiviral agents act by targeting replication of HSV1 DNA, and so the researchers considered that they might be successful in treating AD only if the accumulation of β-amyloid and P-tau accumulation caused by the virus occurs at or after the stage at which viral DNA replication occurs.
“If these proteins are produced independently of HSV1 replication, antivirals might not be effective,” said Professor Itzhaki. “We investigated this and found that treatment of HSV1-infected cells with acyclovir, the most commonly used antiviral agent, and also with two other antivirals, did indeed decrease the accumulation of β-amyloid and P-tau, as well as decreasing HSV1 replication as we would expect.
“This is the first study investigating antiviral effects on AD-like changes and we conclude that since antiviral agents reduce greatly β-amyloid and P-tau levels in HSV1-infected cells, they would be suitable for treating Alzheimer’s disease. The great advantage over current AD therapies is that acyclovir would target only the virus, not the host cell or normal uninfected cells. Further, these agents are very safe and are relatively inexpensive.
“Also, by targeting a cause of Alzheimer’s disease, other viral damage, besides β-amyloid and P-tau, which might be involved in the disease’s pathogenesis, would also be inhibited.
“The next stage of our research – subject to funding – will focus on finding the most suitable antiviral agent – or combination of two agents that operate via different mechanisms – for use as treatment. We then need to investigate the way in which the virus and the genetic risk factor interact to cause the disease, as that might lead to further novel treatments.
“Eventually, we hope to begin clinical trials in humans but this is still some way off yet and again will require new funding.”
The study, carried out with Dr Matthew Wozniak and other colleagues in the Faculty of Life Sciences, is published in the Public Library of Science (PLoS) One journal
Subscribe to:
Posts (Atom)

